Skip to main content

Drug Interactions between Botox and Raplon

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

rapacuronium onabotulinumtoxinA

Applies to: Raplon (rapacuronium) and Botox (onabotulinumtoxinA)

MONITOR CLOSELY: The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission. Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.

MANAGEMENT: Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission. These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning. Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection. Swallowing and breathing difficulties may be life-threatening or fatal. Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.

References

  1. "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals PROD
  2. "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc PROD
  3. "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc PROD
  4. "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals (2022):
  5. "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc. (2022):
  6. "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc. 1 (2022):
  7. "Product Information. Letybo (letibotulinumtoxinA)." CROMA Australia Pty Ltd 1 (2022):
  8. "Product Information. Letybo (letibotulinumtoxinA)." Hugel Aesthetics (2024):
View all 8 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer